Demo Dashboard - Treatment recommendations are simulated. Real AI analysis not yet integrated.
Patient Dashboard
Your Clinical Profile
Diagnosis
Stage IIIA Non-Small Cell Lung Cancer
EGFR mutation positive
Treatment History
Chemotherapy completed
Radiation therapy completed
Breakthrough Treatments Found
Phase III96% Match
AMG 510 (Sotorasib)
KRAS G12C inhibitor showing promising results in NSCLC patients with KRAS mutations.
Expected Availability:Q2 2024
Estimated Cost:$12,000/month
FDA Approved89% Match
Osimertinib + Bevacizumab
Combination therapy for EGFR-mutated NSCLC showing improved progression-free survival.
Expected Availability:Available Now
Estimated Cost:$18,000/month
Phase II82% Match
CAR-T Cell Therapy
Personalized immunotherapy showing breakthrough results in solid tumor treatment.
Expected Availability:2025-2026
Estimated Cost:$450,000 one-time
Recent Breakthrough Alerts
New EGFR Inhibitor Shows Promise
Phase III trial results for BLU-945 show 73% response rate in EGFR C797S resistant patients.
2 hours ago
Clinical Trial Enrollment Open
New immunotherapy trial accepting patients with your profile at Johns Hopkins.
1 day ago
Breakthrough Designation Granted
FDA grants breakthrough therapy designation to lorlatinib for ALK-positive NSCLC.
3 days ago